BOPA 2023 | The current state of prostate cancer screening in 2023

Diana Matthews, Velindre Cancer Centre, Cardiff, UK, comments on the current role of screening in prostate caner. Despite relatively low rates of screening, increasing screening rates may be detrimental to patients. Detecting PSA levels and prostate cancer earlier than needed may result in unnecessary treatment for patients who are asymptomatic, and exhaust current lines of therapy earlier. This interview took place at the 26th Annual British Oncology Pharmacy Association (BOPA) Symposium in Newport, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.